Table 2

Demographics and patient characteristics

CharacteristicOverall (n=28)Regimen A (n=19)Regimen B (n=9)
Diagnosis, n (%)
 MSS-CRC15 (54)10 (53)5 (56)
 PR-OC4 (14)2 (11)2 (22)
 ER+HER2- BC9 (32)7 (37)2 (22)
Median age (range) y56 (36–78)58 (36–78)52 (36–64)
Gender
 Male9 (32)8 (42)1 (11)
 Female19 (68)11 (58)8 (89)
ECOG PS
 07 (25)6 (32)1 (11)
 121 (75)13 (68)8 (89)
Prior systemic therapies (range)7 (3–12)7 (3–12)5 (3–8)
Prior treatment
 Surgery28 (100)19 (100)9 (100)
 Radiation18 (64)12 (63)6 (67)
PD-L1 tumor Staining at baseline
 (SP263) ≥ 25%*000
  • *PD-L1 expression in tumor cells was assessed by immunohistochemistry using VENTANA SP263 assay (Roche Diagnostics), with positivity defined as staining in tumor cells >25%.

  • ECOG PS, Eastern Cooperative Oncology Group performance status; ER+HER2- BC, estrogen receptor positive, HER2 negative breast cancer; MSS-CRC, microsatellite stable colorectal cancer; PD-L1, programmed cell death-ligand 1; PR-OC, platinum resistant ovarian cancer.